Methyl-propyl-isoamyl-amin | 98958-24-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Methyl-propyl-isoamyl-amin
• 英文别名: isopentyl-methyl-propyl-amine；N-methyl-N-(3-methylbutyl)-1-propanamine；N,3-dimethyl-N-propylbutan-1-amine
• CAS: 98958-24-8
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: BPCCYOWJQWCMQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Methyl-propyl-isoamyl-amin 在 双氧水 作用下， 生成 isopentyl-methyl-propyl-amine oxide
  参考文献：
  名称：

  Amine Oxides. III. Selective Formation of Olefins from Unsymmetrical Amine Oxides and Quaternary Ammonium Hydroxides¹

  摘要：

  DOI：

  10.1021/ja01574a037
• 作为产物：
  描述：

  3-(二甲基氨基)-2-甲基丙烯 在 镍 氢气 、 sodium amide 作用下， 以 甲醇 、 氨 为溶剂， 生成 Methyl-propyl-isoamyl-amin
  参考文献：
  名称：

  Dietrich,W. et al., Journal fur praktische Chemie (Leipzig 1954), 1976, vol. 318, p. 681 - 692

  摘要：

  DOI：

文献信息

• [EN] MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION<br/>[FR] INTERMÉDIAIRES MONOFONCTIONNELS POUR LA DÉGRADATION D'UNE PROTÉINE CIBLE DÉPENDANTE DU LIGAND
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017176958A1

  公开（公告）日：2017-10-12

  The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.

  本公开提供了由式I表示的化合物及其盐或溶剂合物，其中X、L、Y和B如规范中所定义。具有式I的化合物是免疫调节剂和/或可用于制备小分子药物共轭物的单功能合成中间体。
• Immunomodulating Heterocyclic Compounds
  申请人：Matthews Ian Richard

  公开号：US20090312334A1

  公开（公告）日：2009-12-17

  Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R 1 and R 3 independently represent H; F; Cl; Br; —NO 2 ; —CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or —NHC(═S)NR 7 R 6 wherein R 6 represents H, or a radical of formula -(Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R 8 )— links wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; —NR 9 R 10 wherein R 9 and R 10 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R 9 and R 10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R 6 and n is 0 or 1.

  公式（I）的化合物是CD80的抑制剂，可用于免疫调节治疗：其中，R1和R3分别表示H; F; Cl; Br; -NO2; -CN; C1-C6烷基，所述烷基可选地被F或Cl取代; 或C1-C6烷氧基，所述烷氧基可选地被F取代; R4表示羧酸基(-COOH)或其酯，或-C（═O）NR6R7，-NR7C（═O）R6，-NR7C（═O）OR6，-NHC（═O）NR7R6或-NHC（═S）NR7R6，其中R6表示H，或式-(Alk)m-Q的基团，其中m为0或1，Alk是可选地取代的二价直链或支链C1-C12烷基，或C2-C12烯基，或C2-C12炔基基团或二价C3-C12环烷基基团，其中任何一个基团可以含有一个或多个-O-，-S-或-N（R8）-键，其中R8表示H或C1-C4烷基，C3-C4烯基，C3-C4炔基或C3-C6环烷基，而Q表示H; -NR9R10，其中R9和R10独立地表示H; C1-C4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 可选地取代的环烷基或杂环基; 或者R9和R10与它们所连接的氮一起形成一个环，该环是可选地取代的; 而R7表示H或C1-C6烷基; 或者当R6和R7与它们所连接的原子或原子一起形成一个可选地取代的含5、6或7个环原子的单环杂环时; 而X表示键或式-(Z)n-(Alk)-或-(Alk)-(Z)n-的二价基团，其中Z表示-O-，-S-或-NH-，Alk如在R6中所定义，n为0或1。
• AMINOALCOHOL LIPIDOIDS AND USES THEREOF
  申请人：Mahon Kerry Peter

  公开号：US20100331234A1

  公开（公告）日：2010-12-30

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文介绍了通过将胺与环氧末端化合物反应制备氨基醇脂质体的方法。还提供了从商业起始材料制备氨基醇脂质体的方法。氨基醇脂质体可以从外消旋或立体化学纯的环氧化合物制备。氨基醇脂质体或其盐形式最好是可生物降解和生物相容的，并可用于各种药物递送系统。由于这些氨基醇脂质体化合物的氨基基团，它们特别适用于多核苷酸的递送。已制备包含发明性脂质体和多核苷酸的复合物、胶束、脂质体或颗粒。发明性脂质体还可用于制备药物递送的微粒。鉴于它们缓冲其周围环境pH值的能力，它们特别适用于递送不稳定的药物。
• Aminoalcohol lipidoids and uses thereof
  申请人：Massachusetts Institute of Technology

  公开号：US10189802B2

  公开（公告）日：2019-01-29

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文介绍了通过胺与环氧化物封端化合物反应制备氨基醇脂质的方法。还提供了从市售起始原料制备氨基醇类脂质的方法。氨基醇脂质可由外消旋或立体化学纯环氧化物制备。氨基醇类脂质或其盐类最好具有生物降解性和生物相容性，可用于各种给药系统。考虑到这些氨基醇类脂化合物的氨基，它们特别适合用于多核苷酸的给药。现已制备出含有本发明类脂化合物和多核苷酸的复合物、胶束、脂质体或颗粒。本发明的类脂质还可用于制备给药微粒。由于本发明脂质具有缓冲周围环境 pH 值的能力，因此在递送易变药剂方面特别有用。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3203840B1

  公开（公告）日：2020-08-05